Ultragenyx Pharmaceutical RARE AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's AFS securities?
- Ultragenyx Pharmaceutical (RARE) reported AFS securities of $121M in Q1 2026.
- How has Ultragenyx Pharmaceutical's AFS securities changed year-over-year?
- Ultragenyx Pharmaceutical's AFS securities increased by 76.5% year-over-year, from $68.56M to $121M.
- What is the long-term trend for Ultragenyx Pharmaceutical's AFS securities?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's AFS securities has grown at a 40.2% compound annual growth rate (CAGR), from $10.51M to $57M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.